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Summary
The open reading frame (ORF) 7a of the SARS-associ-
ated coronavirus (SARS-CoV) encodes a unique type
I transmembrane protein of unknown function. We
have determined the 1.8 Å resolution crystal structure
of the N-terminal ectodomain of orf7a, revealing a
compact seven-stranded  sandwich unexpectedly
similar in fold and topology to members of the Ig su-
perfamily. We also demonstrate that, in SARS-CoV-
infected cells, the orf7a protein is expressed and re-
tained intracellularly. Confocal microscopy studies
using orf7a and orf7a/CD4 chimeras implicate the
short cytoplasmic tail and transmembrane domain in
trafficking of the protein within the endoplasmic retic-
ulum and Golgi network. Taken together, our findings
provide a structural and cellular framework in which
to explore the role of orf7a in SARS-CoV patho-
genesis.
Introduction
Severe acute respiratory syndrome (SARS) is an atypi-
cal pneumonia displaying unusually high rates of mor-
bidity and mortality (Stadler et al., 2003). The illness is
a direct result of infection by a coronavirus (SARS-CoV)
that was first identified in March of 2003. SARS-CoV is
sufficiently divergent from all previously identified coro-
naviruses that it may represent a distinct lineage (Marra
et al., 2003; Rota et al., 2003). Current evidence sug-
gests the virus emerged from nonhuman sources (Guan
et al., 2003; Yu et al., 2003), possibly as a recombination
event between mammalian-like and avian-like parent
viruses (Rest and Mindell, 2003; Stanhope et al., 2004;
Stavrinides and Guttman, 2004).
The genomic sequences of numerous SARS-CoV iso-
lates have been determined (http://www.ncbi.nlm.nih.
gov/genomes/SARS/SARS.html). The principal “con-
served” open reading frames occur in the same order
and are of similar size as those found in other coro-
naviruses. These include, from 5# to 3#, genes for the
replicase (rep), spike (S), envelope (E), membrane (M),
and nucleocapsid (N) proteins. In addition to the con-
served genes, six or more novel open reading frames*Correspondence: fremont@pathbox.wustl.eduare predicted at the 3# end of the SARS-CoV genome
(ORFs 3a, 3b, 7a, 7b, 8ab, and 9b) (Snijder et al., 2003).
So far, the functions of these genes remain unknown.
Their absence from other genomes suggests that they
might carry out unique functions in SARS-CoV replica-
tion, assembly, or virulence. Similarly positioned “ac-
cessory genes” have proven dispensable for coro-
navirus viability in vitro, although their deletion often
leads to viral attenuation in vivo (de Haan et al., 2002).
These genes are therefore particularly interesting, con-
sidering that nonessential accessory genes from a wide
array of viruses function to circumvent host innate and
adaptive immune responses (Alcami and Koszinowski,
2000; Ploegh, 1998).
In this study, we examine the product of the SARS-
CoV accessory gene ORF 7a (Snijder et al., 2003) (also
known as ORF 8 or X4) (Marra et al., 2003; Rota et al.,
2003). Sequence analysis predicts that ORF 7a en-
codes a type I transmembrane protein, 122 amino acids
in length, consisting of a 15 residue N-terminal signal
peptide, an 81 residue luminal domain, a 21 residue
transmembrane segment, and a 5 residue cytoplasmic
tail. Although the orf7a sequence has been identified in
all isolates of SARS-CoV collected from both human
and animal sources, it appears to be unique to SARS,
displaying no significant similarity to any other viral or
nonviral protein. Here, we examine the orf7a accessory
protein in an attempt to clarify its biological signifi-
cance and evaluate its potential as a therapeutic target.
Using an E. coli expression system, we have success-
fully produced the luminal domain of orf7a as soluble
protein by oxidative refolding. We have determined the
crystal structure of orf7a to 1.8 Å resolution, revealing
a compact Ig-like domain. In addition, monoclonal anti-
bodies specific for both the native and denatured forms
of orf7a have been produced, allowing for the analysis
of orf7a expression in SARS-CoV-infected cells. Fur-
ther, we examined orf7a cellular trafficking by immuno-
fluorescence microscopy, revealing predominant in-
tracellular retention within the Golgi network that is
mediated by the transmembrane and short cytoplasmic
tail of the protein.
Results
Production of Soluble Refolded Orf7a Protein
We initiated our studies of orf7a by cloning a cDNA
fragment encoding the mature N-terminal ectodomain
into a bacterial expression vector. Based on the pres-
ence of four cysteine residues and a predicted secre-
tory signal peptide, we expected that two disulfide
bonds would be required for proper folding of the orf7a
ectodomain. Indeed, the bacterially expressed recom-
binant protein proved insoluble. It was therefore recov-
ered from inclusion bodies, denatured in guanidine hy-
drochloride, and then oxidatively refolded by rapid
dilution. The resulting soluble protein was purified on
size exclusion chromatography eluting at w9 kDa, the
correct calibrated molecular weight expected for the
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76compactly folded monomer. We verified the identity of m
rthe orf7a ectodomain fragment by electrospray mass
dspectrometry (see Experimental Procedures). The ob-
aserved mass is consistent with two disulfide bonds in
rthe refolded molecule. The protein runs as a single spe-
rcies on native PAGE and is stable in solution at 10 mg/
ml over a period of several weeks.
s
a
Structure of the Orf7a Luminal Domain e
We next initiated a structural-genomics-type examina- t
tion of orf7a. We hoped to gain insight into the potential S
function of orf7a by investigating the structural relation- h
ships between orf7a and other well-characterized pro- m
teins. Crystallization screening of the refolded orf7a a
protein yielded diffraction-quality hexagonal crystals v
belonging to space group P31 (a = b = 37.10 Å, c = w
55.33 Å), which grew over a 3 day period in hanging o
drops to an approximate size of 0.2 × 0.1 × 0.1 mm. n
Initial phasing was accomplished by multiple isomor- t
phous replacement (MIR) using data collected from three n
different Pt heavy atom derivatives (Table 1). The result- T
ing electron density maps were readily interpretable A
(Figure 1A). An initial model, spanning residues 1–67 t
without a main chain break, was obtained directly from
experimental phase using the autobuild feature of ARP/ p
wARP (Morris et al., 2003). Further refinement was car- t
ried out in CNS with only minor model building required m
in O (Jones et al., 1991). The final model has excellent c
fgeometry, with 94.8% of all residues residing in theTable 1. Summary of Data Collection, Phasing, and Refinement for SARS Orf7a
Data Collectiona
Space group and unit cell (Å) P31 a = b = 37.10 Å, c = 55.33 Å
Data set native K2Pt(CN)4 K2Pt(NO2)4 K2PtCl4
Wavelength (Å) 0.90 1.5418 0.90 0.90
X-ray source APS 14BMb Rigaku APS 14BM APS 14BM
Resolution (Å) (outer shell) 20–1.8 (1.88–1.8) 20–2.0 (2.09–2.0) 20–2.0 (2.09–2.0) 20–2.0 (2.09–2.0)
Observations/unique 55,822/7,744 41,928/5,770 25,115/5,656 101,513/5,759
Completeness (%) 98.7 (100) 99.3 (98.4) 99.2 (100) 99.1 (98.7)
Rsym (%) 4.7 (29.7) 7.3 (74.5) 2.9 (14.8) 5.1 (32.1)
I/σ 34.9 (5.2) 25.5 (1.9) 47.7 (10.3) 25.0 (4.0)
MIR Phasing Statisticsc
Heavy atom sites 1 1 2
Rcullis isomorphous/anomalous 0.77/0.98 0.85/0.95 0.86/0.99
Phasing power isomorphous/ 0.98/0.35 0.58/0.55 0.55/0.28
anomalous
Figure of merit 0.38
Refinement Summaryd
Resolution (Å) 20–1.8 (1.88–1.8)
Reflections Rwork/Rfree 7,741 (422)
No. protein atoms/solvent 534/142
Rwork overall (outer shell) (%) 22.3 (30.1)
Rfree overall (outer shell) (%) 27.5 (31.8)
Rmsd bond length (Å)/angles (°) 0.005/1.3
Rmsd dihedral/improper (°) 25.8/0.69
Ramachandran plot
Most favored/additional (%) 94.8/5.2
Est. coordinate error (Å) 0.24
a Values as defined in SCALEPACK (Otwinowski and Minor, 1997).
b Advanced Photon Source, Beamline 14BM.
c Values as defined in SHARP (Morris et al., 2003).
d Values as defined in CNS (Brunger et al., 1998).ost favored region of the Ramachandran plot and the
emaining 5.2% in the additionally allowed region as
efined by PROCHECK (Laskowski et al., 1993). There
re no residues in the disallowed or generously allowed
egions. The final model has an Rwork of 22.3% to 1.8 Å
esolution, with an Rfree of 27.5%.
Our model for the orf7a luminal domain consists of
even β strands which form two β sheets, compactly
rranged in an Ig-like β sandwich fold (Figure 1B). How-
ver, the precise topology of orf7a is distinctive from
hat of typical Ig-superfamily members (Figure 1C).
trand A, instead of running antiparallel to strand B,
as switched sheets and lies parallel to strand G. Like
any C1-type Ig domains, both the C# and C$ strands
re absent. In addition, the C and D strands are both
ery short: the C strand is only 4 amino acids in length,
hile the D strand is just 3 residues long. The structure
f orf7a also contains two unusual disulfide bonds con-
ecting the BED and AGFC sheets. Neither occurs in
he typical position occupied by the Ig-superfamily ca-
onical disulfide (i.e., connecting the B and F strands).
he first disulfide of orf7a connects the end of strand
to the E-F loop, while the second disulfide connects
he short B-C and F-G loops.
We sought to identify proteins of similar topology by
erforming a Dali search (Holm and Sander, 1995). The
wo most similar structures identified were the N-ter-
inal domain of the human intercellular adhesion mole-
ule-2 (ICAM-2) (Protein Data Bank [PDB] ID 1ZXQ,
ragment 1–85, rmsd of 2.3 Å for 55 aligned residues,
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(A) Stereoview of the 2Fo − Fc electron density composite omit map shown as gray mesh with orf7a residues depicted as a ball-and-stick
model. The view is of the F-G loop drawn at a contour level of 2σ.
(B) Ribbon trace of the orf7a luminal domain showing the two sheets of the Ig-like β sandwich. The disulfides are labeled by their Cys
positions. Two reported polymorphisms (Gly23 and His47) are indicated in silver.
(C) Topological diagram of the orf7a fold. A dashed line separates the BED and AGFC sheets. The β strands are labeled A–G and displayed
in green.
(D) Structure-based alignment of orf7a with the N-terminal domains of IL-1R and ICAM-2. The β strands in each are highlighted in green, and
Cys residues are in yellow. Symbols indicating the solvent accessibility of the orf7a side chains are shown below each position. Filled circles
represent greater than 60% solvent inaccessible, half-filled between 30% and 60% inaccessible, and empty circles less than 30% inaccessi-
ble. Regions within the orf7a sequence are labeled: signal peptide, stalk, transmembrane (Tm), and cytoplasmic tail. Positions of polymor-
phism are indicated with asterisks.with 6% sequence identity) and the N-terminal domain
of the human interleukin-1 receptor (IL-1R) (PDB ID
1IRA, fragment 1–94, rmsd of 2.0 Å for 46 aligned resi-
dues, with 11% sequence identity). Both structures are
considered examples of I-set Ig domains as defined by
SCOP (Murzin et al., 1995). Comparisons of orf7a with
55 additional members of the Ig superfamily identified
by Dali revealed sequence identities ranging from 2%
to 16% for aligned core residues, consistent with our
failure to predict an Ig-like fold from the primary se-
quence alone. Also, compared with most Ig folds, the
orf7a luminal domain is extremely small, consisting of
only 65 amino acids. For comparison, the average
length of an I-set domain in HOMSTRAD (Mizuguchi et
al., 1998) is 98 amino acids. In addition to the short C
and D strands, the membrane-distal B-C and F-G loops
are also comparatively short. These differences are
best seen in the structure-based alignment of the I-set
domains with orf7a (Figure 1D).
Localization of Orf7a in SARS-CoV-Infected Cells
In order to characterize the expression and intracellular
trafficking of orf7a, we generated monoclonal antibod-
ies (mAbs) specific for the luminal domain. Recombi-
nant soluble-refolded orf7a protein was used to immu-
nize mice. Solid-phase ELISA identified 24 hybridomas
producing mAb specific for the refolded protein. These
were characterized in cell staining, Western blotting,and immunoprecipitation assays (Table 2A). To prove
that the IgG2b isotype clone 2E11 was specific for na-
tive orf7a, immunoprecipitation studies were performed
using lysate from SARS-CoV-infected cells. Vero cells
were infected with SARS-CoV at a multiplicity of infec-
tion (moi) of 0.01 for 48 hr in accordance with the rules
and regulations of Washington University and the “Lab-
oratory Biosafety Guidelines for Handling and Process-
ing Specimens Associated with SARS-CoV” as put for-
ward by the Department of Health and Human Services
Centers for Disease Control and Prevention (CDC). All
manipulation of infectious samples took place in a BSL-3
biological safety facility. The infected cells were washed,
solubilized in 1.0% Triton X-100, and immune com-
plexes were recovered on protein A Sepharose. As ex-
pected, the 2E11 clone immunoprecipitated a single
band of w12 kDa. This protein was identified as orf7a
by N-terminal sequencing (Table 2B). An identical se-
quence was obtained using lysate from 293T cells
transfected with an orf7a cDNA. In both cases, the pre-
dicted 15 amino acid signal peptide (MKIILFLTLIVFTSC)
of orf7a had been removed, presumably by signal pep-
tidase cleavage. These results and the inability of 2E11
to recognize denatured (boiled-reduced) recombinant
orf7a protein on Western blot support the conclusion
that 2E11 is specific for orf7a in its natively expressed
form. The ability of the conformation-dependent 2E11
mAb (raised against recombinant, refolded orf7a) to im-
Structure
78Table 2. Characterization of Monoclonal Antibodies and Orf7a N-Terminal Sequencing
A. Representative Set of Anti-Orf7a Hybridomas
Permeabilized Cell Nonboiled
Hybridoma Isotype Staininga Boiled Reducedb Nonreducedb IP Triton X-100c
2E11 IgG2b ++++ — ++++ ++++
1H4 IgG1 +++ — ++++ +++
3B1 IgG1 ++ — ++ +
1A2 IgG1 +++ ++ — +
2F6 IgG3 + ++++ — +
1D10 IgG3 ++ ++++ — +
B. N-Terminal Protein Sequencing of Orf7a Immunoprecipitated with the 2E11 Monoclonal Antibody
Source Peptide Sequence Positions
SARS-CoV-infected Vero cellsd ELYHYQE(X)fVRGTTV 1–14
Orf7a-transfected 293T cellse ELYHYQE(X)VRGTTV 1–14
a Assessed by FACS using 1% saponin-treated cells.
b Treatment of recombinant orf7a before Western blot.
c Immunoprecipitation in 1% Triton X-100.
d Cell lysates prepared from Vero cells at 48 hr postinfection.
e Cell lysates prepared from 293T cells transfected with an orf7a cDNA at 72 hr.
f The amino acid cysteine cannot be observed by this method, as indicated by (X).munoprecipitate orf7a protein from SARS-CoV-infected c
Tcells strongly suggests that the conformation of the re-
folded and natively expressed proteins is similar if not s
Gidentical. Final confirmation of this awaits the de-
velopment of assays for the as yet unknown function s
Aof orf7a.
We next examined the expression of ORF 7a in t
rSARS-CoV-infected cells by confocal microscopy using
the 2E11 antibody. Infected Vero cells were fixed and a
tstained for either SARS-CoV S protein (Figures 2A and
2B) or orf7a (Figures 2C and 2D). While the S protein a
Gwas readily detectable at the plasma membrane, little
orf7a could be detected. Permeabilization of SARS-
CoV-infected cells with saponin significantly increased L
the orf7a staining, demonstrating that the majority of a
orf7a remains intracellular (mainly in the perinuclear re- T
gion; Figures 2E and 2F). t
(
sLocalization Studies of Orf7a in Cell Transfectants
Vero cells transfected with an ORF 7a cDNA showed a e
fsimilar pattern; intact cells displayed little surface orf7a
staining, while permeabilized cells displayed intense in- c
ptracellular staining (Figures 2G and 2H). From this result,
we conclude that orf7a does not require the expression 2
wof other viral proteins for its intracellular trafficking and
retention. To facilitate analysis of the intracellular distri- t
Abution, a green fluorescence protein (GFP) tag was
fused in-frame to the carboxyl terminus. The fluores- a
tcent pattern was clearly distinct from GFP alone (Figure
2K). The fusion tag also did not alter the observed intra- o
rcellular distribution of orf7a; the majority of the orf7a-
GFP was still retained in a perinuclear location (Figures 3
2I and 2J).
We confirmed the low level of cell-surface expression t
iof orf7a by flow cytometry using 293T cells transfected
with an orf7a-GFP cDNA. Intact cells displayed little s
iorf7a-positive/GFP-positive staining, whereas saponin-
permeabilized cells showed a significant increase in the s
pdouble-positive population (Figure 3A, upper panels).
Next, permeabilized Vero cell transfectants were stained m
using an antibody to Golgin 97, a protein known to lo-alize in the trans-Golgi network (Griffith et al., 1997).
he merged composite images (Figure 3B, top row)
how a strong colocalization between orf7a-GFP and
olgin 97 staining. A much weaker association was
een with the ER marker calnexin (Galvin et al., 1992).
lthough differences in the fixation procedures and an-
ibodies used make a direct comparison difficult, these
esults are in general agreement with that of Fielding et
l., who resolved perinuclear localization of orf7a with
he subcellular markers GRP94 and Sec 31 (Fielding et
l., 2004), collectively placing orf7a in the ER and
olgi compartments.
ocalization Studies of Orf7a Variants
nd Orf7a/CD4 Chimeras
he short orf7a cytoplasmic tail contains three posi-
ively charged residues proximal to the membrane
Lys103, Arg104, and Lys105 in Figure 1D). This triplet
equence ([Arg/Lys][X][Arg/Lys]) has been found in sev-
ral Golgi resident proteins and appears to be required
or recognition by the COPII vesicular system impli-
ated in the transport of proteins from ER to Golgi com-
artments (Giraudo and Maccioni, 2003; Bickford et al.,
004). To examine the role of the orf7a cytoplasmic tail,
e constructed a mutant orf7a-GFP fusion in which the
wo Lys tail residues were changed to Ala. The orf7a-
A-GFP tail mutant, like the wild-type, displayed only
low level of expression at the plasma membrane of
ransfected cells (Figure 3A, lower panels). The majority
f the mutant protein colocalized with antibodies di-
ected against the ER resident protein calnexin (Figure
B, bottom row).
The extremely short length of the orf7a cytoplasmic
ail (five amino acids) suggested that additional targeting
nformation might exist elsewhere in the protein. Not
urprisingly, transfer of the orf7a cytoplasmic tail was
nsufficient to confer intracellular retention on the cell-
urface protein CD4 (Figure 4A, compare the first two
anels). In contrast, transfer of both the orf7a trans-
embrane domain and cytoplasmic tail (26 aminoacids) resulted in an increase in the amount of CD4
SARS-CoV Orf7a Structure and Localization
79Figure 2. Intracellular Retention of Orf7a
Vero cells were either mock infected ([A], [C], and [E]) or infected with SARS-CoV ([B], [D], and [F]) for 18 hr at an moi of 5. As expected, the
spike protein was clearly present at the surface of the SARS-CoV-infected but not mock-infected cells ([A] and [B]). Incubation with the anti-
orf7a monoclonal antibody 2E11 demonstrated only limited cell-surface expression of orf7a. An intracellular pool of orf7a was clearly evident
after saponin permeabilization ([E] and [F]). The anti-SARS antibody is a mixture of hybridoma supernatants specific for SARS proteins and
found to primarily recognize the S protein by Western blotting (a gift of Larry Anderson, CDC). Intracellular retention of orf7a does not require
other viral proteins. When an orf7a cDNA is used to transiently transfect 293T cells, very little orf7a can be detected at the cell surface using
2E11 (G). Again, saponin pretreatment allowed staining of the intracellular orf7a (H). Addition of a C-terminal GFP tag did not significantly
alter this intracellular distribution. A good colocalization was observed between orf7a staining (red) and GFP fluorescence (green) in this
transfectant ([I] and [J]). The orf7a-GFP distribution was distinct from that seen for GFP alone (K).marker protein retained in the Golgi, as seen by com-
paring the colocalization of this chimeric construct with
Golgin 97 (Figure 4B). However, localization of the CD4/
orf7a TM tail construct was not as tight as that seen for
orf7a alone, suggesting that residues in the orf7a stalk
or luminal domain may also contribute to orf7a intracel-
lular targeting. This situation, where residues outside
the transmembrane domain help to fine-tune localiza-
tion within the Golgi, has been observed for other mem-
brane bound Golgi-resident proteins (Burke et al.,
1994). Still, the dramatic difference between the CD4/
orf7a TM tail and the CD4-GFP localizations indicates
that the targeting signal exists primarily within the
transmembrane and cytoplasmic tail.
Discussion
Our structural studies of the orf7a luminal domain have
established that it adopts an extremely compact Ig-like
β sandwich fold topology, despite an absence of signifi-
cant sequence similarity to other members of the Ig su-perfamily. This common structural fold occurs in a wide
variety of proteins, where it performs a diverse set of
functions. For example, the fold is found in proteins of
the extracellular matrix, muscle proteins, proteins of the
immune system, cell-surface receptors, enzymes, tran-
scription factors, and a wide variety of viral proteins
(Clarke et al., 1999). An automated comparison of the
luminal domain against 189 active site templates re-
vealed no obvious enzymatic sites (Watson et al., 2003).
Further, comparison of the structure with Ig superfamily
members did not reveal any obvious conserved func-
tional regions. As a result, we find it difficult to draw
conclusions about the function of orf7a from the struc-
ture alone. Still, some features are worth noting. Be-
cause of the unusual disulfide-bonding pattern, the two
β sheets bow away from each other in the middle. This
separation allows the formation of a deep hydrophobic
pocket near the middle of the A strand. In most Ig folds,
the B strand hydrogen bonds with the A strand. In
orf7a, the peptide backbone of the B strand is free and
passes close to the deep hydrophobic A pocket (Figure
Structure
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(A) Flow cytometry analysis of protein expression levels on 293T cell transfectants. Direct comparison of orf7a-GFP with its cytoplasmic tail
mutant, orf7aAA-GFP, in which Lys103 and Lys105 were replaced by Ala. The extent of transfection is revealed by GFP fluorescence. Both
intact and saponin-permeabilized cells were stained with the anti-orf7a mAb 2E11. Significantly more anti-orf7a mAb staining was seen in
the permeabilized cells, suggesting that the majority of the protein was intracellular.
(B) The same cDNA constructs were introduced into Vero cells and examined by confocal microscopy. Orf7a-GFP colocalizes best with the
Golgi marker Golgin 97 (see Golgin 97 merge in upper row), while orf7a-AA-GFP colocalizes best with the ER resident protein calnexin (see
calnexin merge in lower row). In all cases, the nuclei were counterstained blue with Topro, and the GFP fluorescence appears green. Optical
slices were reconstructed into a three-dimensional image to show colocalization before compression into a two-dimensional representation.5B). Therefore, it may be possible for a peptide strand
tfrom another protein to hydrogen bond with the B
strand while inserting a side chain into the A pocket. t
tSimilar examples of donor-strand binding have been
observed in the assembly of bacterial Ig-superfamily t
schaperones (Sauer et al., 2002). Second, there exists a
deep groove on the backside of the orf7a molecule, L
qformed between the C-D and E-F loops. Interestingly,
one of the few reported sites of polymorphism (His47- p
oAsn47) occurs along this groove and may represent an
adaptation to accommodate a binding partner or d
lligand.Our fluorescence localization studies suggest that
he intracellular retention of orf7a requires both the
ransmembrane and cytosolic tail regions. Transfer of
he orf7a cytoplasmic tail alone onto CD4 (CD4/orf7a-
ail-GFP fusion) was unable to prevent surface expres-
ion of the marker protein. We also found that residues
ys103 and Lys105 of the orf7a cytoplasmic tail are re-
uired for efficient exit from the ER. Several inter-
retations exist for the higher steady-state ER retention
f the Lys minus mutant. First, the charged Lys resi-
ues could serve as a stop-transfer sequence for trans-
ocation of the transmembrane domain. Their substitu-
SARS-CoV Orf7a Structure and Localization
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(A) The majority of the CD4-GFP control protein is seen at the plasma membrane by FACS analysis using intact 293T cells (left). This
distribution did not change when the cytoplasmic tail of CD4 was replaced with that of orf7a (middle). In contrast, significantly more protein
was retained inside the cell when the entire CD4 transmembrane domain and tail were replaced by the orf7a transmembrane domain and
tail (right).
(B) Vero cells expressing the CD4-fusion constructs were permeabilized 24 hr posttransfection and stained for Golgin 97 (red). Confocal
microscopy was used to generate a three-dimensional reconstruction of the cells. Only the merged (Golgin 97 + GFP) images are shown
(lower panels). In all three images, total fluorescence was normalized to the area of the cell displaying the most intense staining (cell surface
for CD4 and CD4-tail, Golgi for CD4-Tm tail).tion to smaller nonpolar Ala residues may disrupt the
conformation of the transmembrane domain or shift its
position within the lipid bilayer enough to destroy re-
cognition of an export signal. At this time, it is unclear
what causes cargo to collect in nascent COPII vesicles
(LaPointe et al., 2004); therefore, it remains possible
that the Lys-Arg-Lys sequence is recognized directly.
Regardless, our data indicate that the charged Lys resi-
dues are important for exit of orf7a from the ER.
How does the trafficking signal in orf7a compare with
other viral ER/Golgi trafficking signals? It is well estab-
lished that the coronavirus E molecule is held in the
Golgi by a signal located in its cytoplasmic tail (Corse
and Machamer, 2002). Little primary sequence homol-
ogy exists between the E proteins of the three coro-
navirus groups. Therefore, the exact trafficking determi-
nant being recognized remains unclear. Still, because
the E signal occurs outside the transmembrane region,
it is most likely different from the orf7a signal. A second
type of Golgi targeting signal occurs in the first trans-membrane domain of the coronavirus M protein (Klum-
perman et al., 1994). Specifically, four polar residues
that line up on one face of a predicted α helix appear
to be critical for the retention of M in the Golgi complex
(Machamer et al., 1993). Here, the lack of polar trans-
membrane residues and different membrane topology
suggest that the orf7a signal operates differently. Sev-
eral single-stranded RNA viruses bud into the Golgi.
For many of these, the principle glycoprotein compo-
nent of the envelope consists of a heterodimeric com-
plex of two single-pass transmembrane proteins. In al-
most every case, the Golgi targeting signal maps to the
transmembrane domain and adjacent carboxy-terminal
residues of one chain of the heterodimer. Examples of
this type include the rubella virus envelope protein E2
(Hobman et al., 1995) and the envelope proteins from
probably all members of the Bunyaviridae family (Bupp
et al., 1996; Shi and Elliott, 2002). No detectable se-
quence homology exists among these regions, and it is
likely that they are conformational in character, making
Structure
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Figure 5. Surface Features of the Orf7a Luminal Domain t
(A) Backbone worm shown in the same orientation as Figure 1B e
(right), and also the reverse orientation (left). s
(B) The molecular surface is shown color coded by curvature to s
highlight local topography. The B strand and A pocket are indi-
fcated. Positions of known polymorphism are labeled. The deep
tgroove that runs along the base of the molecule is indicated.
w(C) Electrostatic potential mapped onto the accessible molecular
surface; blue denotes a net positive charge (+4 kT), and red de- 2
notes a negative (−4 kT). The membrane distal face (top) is primar- b
ily acidic. l
(
c
it difficult to determine their relationship to the orf7a b
signal. a
Why does orf7a contain an intracellular targeting sig- d
nal? Coronaviruses acquire their membrane envelope s
by budding into the lumen of an ER to Golgi intermedi- l
ate compartment (ERGIC) (Klumperman et al., 1994; l
Krijnse-Locker et al., 1994). Three or four viral proteins t
incorporate into this envelope, by far the most abun- f
cdant being the M protein. In cells forced to express My cDNA transfection, a small amount of E is sufficient
o trigger the formation of virus-like particles (Bos et
l., 1996; Vennema et al., 1996). It is still unclear what
akes the M and E proteins gather in the ERGIC during
nfection (Lontok et al., 2004). When expressed individ-
ally, both move past the virus-assembly site (Corse
nd Machamer, 2002; Swift and Machamer, 1991). Two
ther coronavirus proteins integrate into the budding
embrane: the S protein and, in the subset of coro-
aviruses that express it, the hemagglutinin–esterase
HE) protein. Both localize to the pre-Golgi by forming
pecific interactions with M (Nguyen and Hogue, 1998).
f SARS-CoV buds into the ERGIC as other coro-
aviruses do, then our data indicate that orf7a traffics
hrough the budding compartment. It is conceivable
hat orf7a may play a role in viral assembly or budding
vents unique to SARS-CoV. In support of this idea, Tan
t al. have presented coimmunoprecipitation data sug-
esting an interaction between orf7a and the product of
nother SARS-CoV accessory gene, ORF3a, a protein
hich in turn interacts with the structural proteins M,
, and S (Tan et al., 2004). Alternatively, orf7a may itself
e packaged into virions, possibly to serve as a se-
ondary attachment protein in a manner analogous to
E. So far, studies aimed at identifying the structural
roteins of the SARS-CoV virion have failed to detect
rf7a (Krokhin et al., 2003; Ying et al., 2004), although
t is worth noting that these methods also have failed
o detect the virion-associated E protein. We tested
hether our anti-orf7a monoclonal antibodies could
lock the production of virus or its cytopathic effects
n SARS-CoV-infected Vero cells. However, no neutral-
zation effect was observed (data not shown).
What other functions could orf7a serve within the
ontext of the ER/Golgi network? A significant number
f viral accessory proteins have been found to be criti-
al for the evasion of host-mediated immunity, interfer-
ng with diverse processes, including apoptosis, com-
lement activation, cytokine signaling, and innate and
daptive immune surveillance (Alcami and Koszinow-
ki, 2000; Ploegh, 1998). While many of these proteins
ct at the plasma membrane or are secreted from in-
ected cells, others have been found to operate within
he secretory pathway, where they downregulate a vari-
ty of cell surface receptors, including signaling, co-
timulatory, and adhesion molecules. For example,
everal viral accessory proteins have evolved to speci-
ically prevent activation of NK or CD8 T cells by in-
erfering with classical and nonclassical MHC function
ithin ER and/or Golgi compartments (Orange et al.,
002). The murine cytomegalovirus m152 protein
locks surface expression of MHC class I as well as
igands of NKG2D by sequestering them in the ERGIC
Lodoen et al., 2003; Ziegler et al., 1997). The human
ytomegalovirus US2 and US11 proteins, which are
oth like orf7a (type I transmembrane proteins that
dopt Ig-like folds [Gewurz et al., 2001]), catalyze the
islocation of MHC class I molecules from ER to cyto-
ol; this dislocation results in its rapid degradation (Lil-
ey and Ploegh, 2004; Ye et al., 2004). The bovine papil-
omavirus E5 protein retains MHC class I molecules in
he Golgi and prevents their transport to the cell sur-
ace (Marchetti et al., 2002). RNA viruses can also en-
ode MHC subversion proteins. For example, HIV-1 uses
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83Nef to selectively downregulate HLA-A and HLA-B (Co-
hen et al., 1999). To see whether orf7a might have an
analogous immunomodulatory function, we examined
293T cells transiently transfected with orf7a by flow
cytometry. Our preliminary experiments indicated that
orf7a expression does not result in significant loss of
HLA-A expression (data not shown). The possible inter-
ference of orf7a with other immune surveillance mecha-
nisms is currently under investigation.
To date, significant progress has been made in un-
derstanding those genes common to all coronaviruses
encoding “essential” replication or structural functions.
However, comparatively little is known about the coro-
navirus group-specific “accessory” genes. To help elu-
cidate the significance of one of these, we have deter-
mined the structure and subcellular localization of
SARS-CoV orf7a. Our results establish a structural and
cellular framework for experiments directed at under-
standing the function of orf7a within the SARS-CoV life
cycle. Toward this end, we are pursuing both biochemi-
cal and genetic approaches to identify potential orf7a
molecular interactions, as these may prove suitable as
targets for antiviral intervention.
Experimental Procedures
Protein Expression and Refolding
A fragment of ORF 7a cDNA encoding amino acids −2 through 81
was inserted between the NcoI and BamHI sites of the bacterial
expression vector pET-21a. This plasmid was introduced into
BL21(DE3)-RIL codon (+) E. coli cells for expression. Recombinant
protein was recovered as an inclusion body pellet, denatured, re-
duced, and then renatured by rapid dilution in refolding buffer con-
sisting of 1 M arginine, 100 mM Tris-HCl, 2 mM EDTA, 200 µM
PMSF, 5 mM reduced glutathione, and 500 µM oxidized glutathione
at a final pH of 8.3. After 24 hr, the soluble-refolded protein was
collected over YM10 membrane in a stirred cell concentrator,
passed through a 0.45 m filter, and subjected to sizing on Super-
dex 200 using an AKTA-FPLC. The original cDNA clone differed by
a single nucleotide from the published sequence (C/A at position
27,360 as numbered in NCBI Accession No. AY278741.1). All of our
constructs maintain the resulting Leu15 to Ile15 replacement. The
final recombinant fragment of orf7a spanned amino acid residues
M(−3)SC/ELY···EEVQQE81* and contained no extraneous tags.
Crystal Growth and Preparation
Purified orf7a protein (8 mg/ml in 20 mM HEPES [pH 7.4], 20 mM
NaCl) was mixed with an equal volume of reservoir solution con-
taining 16% polypropylene glycol 400 and 100 mM NaOAc/HCl at
pH 5.35, then left to equilibrate in hanging drops. Hexagonal crys-
tals belonging to space group P31 (a = b = 37.10 Å, c = 55.33 Å)
grew as triangular rods. These crystals were prepared for flash
cooling at 100 K by transfer into reservoir solution containing 20%
ethylene glycol for about 20 s. Heavy-atom Pt derivatives were
used to determine the initial phasing by multiple isomorphous re-
placement (MIR). Fresh 10 mM stock solutions of potassium tetra-
cyanoplatinate (II) [K2Pt(CN)4], potassium tetrachloroplatinate (II)
(K2PtCl4), and potassium tetranitroplatinate (II) [K2Pt(NO2)4] were
prepared in well solution. Hanging drops containing crystals were
supplemented with one-tenth volume of heavy-atom stock solution
and held at room temperature for various times.
Data Collection and Model Refinement
Single-wavelength diffraction data were collected on our home
source and at the Advance Photon Source Beamline ID-14BM (Ar-
gonne National Laboratory) (Table 1). Data were integrated and
scaled with DENZO, SCALEPACK, and HKL2000 (Otwinowski and
Minor, 1997). Heavy-atom sites were located in CNS (Brunger et al.,
1998) and refined with SOLVE (Terwilliger and Berendzen, 1999). Arandom set of reflections containing 5% of the data was excluded
from the refinement for calculation of Rfree. The experimental
electron density map was subjected to density modification with
DM (Cowtan, 1994). The experimental phase maps are of excep-
tional quality at 2.2 Å. There is no electron density for the first 2 and
the last 14 amino acid residues of the 84 encoded by the construct.
Solvent accessibilities were calculated with NACCESS (probe ra-
dius 1.4 Å) (Hubbard et al., 1991). Molecular diagrams were drawn
using the programs GRASP (Nicholls et al., 1993) and RIBBONS
(Carson, 1991).
Antibody Generation
BALB/c mice were immunized intraperitoneally with 25 g of re-
combinant orf7a protein in 0.2 ml of Ribi adjuvant (Corixa) and
boosted twice at 21 day intervals using the same formulation. Test
bleeds were used to select a single mouse for fusion. This mouse
was boosted intravenously with 5 g protein diluted in PBS 14 days
after its last injection. Three days later, the animal was sacrificed
and the spleen was removed. The murine nonsecreting myeloma
cell line P3x63Ag8.653 was used as the partner in a standard PEG
1500 fusion. Hybridomas were seeded directly into 96-well plates
containing peritoneal macrophages as feeder cells. After 10 days
of selection in hypoxanthine, aminopterin, and thymidine solutions
(HAT), supernatants were screened by ELISA for anti-orf7a mAbs
using solid-phase orf7a protein. Positive hybridomas were ex-
panded in Iscove’s modified Dulbecco’s medium containing HT,
20% FBS (low IgG fetal bovine serum, Hyclone), 3% hybridoma
cloning growth factor (IGEN), 4 mM L-glutamine, and antibiotics,
then cloned by limiting dilution.
Immunoprecipitations and N-Terminal Sequencing
Vero cells were infected with SARS-CoV (Urbani) at an moi of 0.01.
At 48 hr postinfection, the cells were washed in 50 mM HEPES (pH
7.5), 1 mM EGTA, 1500 µM MgCl2, 150 mM NaCl, and 1× complete
protease inhibitors (Roche), then suspended at 1 × 107 cells/ml in
the same buffer. The cells were lysed with an equal volume of 2.0%
Triton X-100 in 150 mM NaCl. After centrifugation, supernatants
were precleared with protein A Sepharose. The anti-orf7a mAb
2E11 was added to 10 g/ml and held 60 min at 4°C. Immune com-
plexes were recovered on protein A Sepharose and washed in cold
lysis buffer without protease inhibitors before being heated to 90°C
in loading buffer (62.5 mM Tris-HCl [pH 6.0], 2% SDS, 5% 2-mer-
captoethanol, 500 mM sucrose) for 5 min. After separation on SDS-
PAGE, the proteins were transferred to polyvinylidene difluoride
membrane. The blot was rinsed in distilled water and then metha-
nol before soaking 2 min in 1.1% w/v Coomassie blue, 40% v/v
methanol/water, and 1% acetic acid. Several changes of 50%
methanol were required to destain the blot. The orf7a region was
excised for N-terminal sequencing (Table 2B).
Orf7a and CD4 Fusion Constructs
ORF 7a was also cloned into the mammalian expression vector
pEGFP-N1 (BD Biosciences) downstream of the CMV promoter and
in-frame with the GFP fusion tag. NheI and BamHI restriction sites
were engineered to flank the insert. The resulting orf7a/linker/GFP
fusion gene encodes MAIILF···IKRKTE/DPPVAT/MVSKG···DELYK*.
Similarly, a full-length cDNA encoding human CD4 (nucleotides 153–
1529 in accession number NM_000616) was inserted in pEGFP-N1 in-
frame with the GFP tag. The resulting CD4/linker/GFP fusion protein
spanned MARGVP···CSPI/EDPPVAT/MVSKG···DELYK*. Two chimeric
fusion genes were made from these constructs, a CD4/orf7a tail-
GFP fusion having the amino acid sequence MARGVP···IFFCV/
KRKTE/DPPVAT/MVSKG···DELYK* and a CD4/orf7a TM tail-GFP fu-
sion having the sequence MARGVP···TWSTPVD/LYSPL···KRKTE/
DPPVAT/MVSKG···DELYK*. Orf7aAA-GFP was made by changing
the orf7a cytoplasmic tail sequence from KRKTE to ARATE.
Immunofluorescence Localizations
Vero E6 (ATCC CRL-1586) and 293T/17 (CRL-11268) cells were cul-
tured in DMEM supplemented with 10% heat-inactivated fetal bo-
vine serum, 1 mM glutamine, and 100 U/ml penicillin/streptomycin.
The cells were incubated in a 95% air, 5% CO2 humidified incubator
at 37°C. Vero cells were plated onto glass cover slips in 3.5 cm
Structure
84diameter tissue culture dishes and incubated overnight at 37°C. B
tThe cells were transfected using the LT-1 (Mirrus) transfection rea-
gent (1 g plasmid DNA and 4 l of transfection reagent per dish) 1
as previously described (Pekosz and Lamb, 1999). Eighteen hours B
posttransfection, the cells were washed in PBS and fixed in 1% S
methanol-free formaldehyde for 10 min at room temperature. After p
extensive washing in PBS, the cells were incubated with antibody V
diluted in PBS containing 3% normal goat sera for 1 hr. The cells
B
were washed three times with PBS and then incubated with a se-
G
condary antibody for 30 min as appropriate. The cover slips were
P
mounted onto microscope slides using Prolong (Molecular Probes)
s
and visualized on a Zeiss LSM 510 confocal microscope. Primary
C
antibodies used were 2E11 (anti-orf7a, 1:100 dilution mouse mono-
Bclonal), anti Golgin 97 (Sigma, 1:500 dilution, mouse monoclonal),
oor anti-calnexin (Sigma, 1:500 dilution, rabbit polyclonal). Second-
vary antibodies include goat anti-mouse IgG or goat anti-rabbit IgG
conjugated to Alexafluor 594 (Molecular Probes; 1:500 dilution). B
When appropriate, cells were permeabilized by the addition of d
0.1% saponin to all buffers postfixation. Nuclei were counter- t
stained with Topro included with the secondary antibody. 1
C
Fluorescence-Activated Cell Sorting
C
293T or Vero cells were plated overnight onto 3.5 cm dishes. The
s
cells were transfected with the indicated plasmids (1 g plasmid
t
per dish, 2 or 4 l of transfection reagent for 293T or Vero cells,
1
respectively) and stained for flow cytometry as previously de-
Cscribed (Pekosz and Lamb, 1999). Primary antibody 2E11 (dilution
B1:100 of 2.4 mg/ml stock) was followed by goat anti-mouse IgG
dconjugated to Alexafluor 647 (Molecular Probes; 1:1000 dilution) or
tanti-human CD4 conjugated to Tri-color (Caltag; 1:500 dilution).
1The cells were analyzed on a FACSCalibur flow cytometer using
CellQuest software. C
t
Mass Spectrometry 1
The sequence of the orf7a luminal domain construct (MSCEL.... C
EVQQE*) predicts a molecular weight of 9412.55 Amu without the p
N-terminal Met (usually removed by endogenous amino-peptidase N
activity). To prepare a sample for electrospray mass spectrometry
d(ESMS), 10 g of protein was brought to a volume of 100 l in water
(and mixed with 100 l of 20% trichloroacetic acid. This mixture
twas held on ice for 30 min. The sample was spun in a microfuge at
n16,000 × g at 4°C for 20 min. The precipitate was washed with 300
Fl of cold acetone and spun again at 16,000 × g at 4°C for 5 min.
HThe protein pellet was air dried and resuspended in 20 l of 60%
sacetonitrile with 0.1% formic acid for analysis. ESMS yielded the
cexpected molecular weight but also a smaller fragment corre-
sponding to a loss of nine amino acids from the stalk at the C G
terminus. The protein used for the crystallization trials contained a C
mixture of the full-length and truncated forms. The observed (
weights also indicate two disulfide bonds per monomer, with the i
extra cysteine capped by glutathione (briefly, 9713.81 Amu = A
9412.55 fragment − 5.04 Amu for 5 Hs + 306.3 Amu for oxidized
Gglutathione, and similarly 8573.59 Amu = 8272.33 Amu fragment −
a5.04 Amu for 5 Hs + 306.3 Amu for oxidized glutathione).
o
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